Trump Administration Settles Lawsuit Barring Federal Agencies from Pressuring Social Media Censorship 
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Palestinian Activist Leqaa Kordia Released from U.S. Immigration Detention After Judge's Order 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Microsoft Backs Anthropic in Legal Fight Against Pentagon's AI Blacklist 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
ICE Arrests Colombian Journalist in Tennessee, Trump Administration Says She Will Receive Due Process 
FEMA Reinstates $1 Billion Disaster Prevention Grant Program After Court Order 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Chemours, Dupont De Nemours, and Corteva have announced a $110 million settlement with the U.S. state of Ohio to resolve claims linked to toxic "forever chemicals." This agreement aims to address concerns surrounding per- and polyfluoroalkyl substances (PFAS).
Nasdaq reported that the chemical has been associated with various health risks. The settlement covers costs related to the release of PFAS from the companies' facilities, including the Washington Works site situated along the Ohio-West Virginia border, as per Reuters.
Responsibility Distribution for Settlement Costs
According to the agreement, Chemours, a spin-off of DuPont, will bear 50% of the settlement costs, while DuPont will contribute approximately $39 million. Corteva, on the other hand, is expected to cover the remaining expenses. The resolution brings an end to Ohio's claims concerning the release of PFAS, affording the state an opportunity to address this issue comprehensively.
The resolution of the Ohio settlement emphasizes the importance of addressing the wide-reaching implications of PFAS contamination.
Notably, the settlement between the companies and Ohio has triggered a contingency provision outlined in Delaware's 2021 PFAS settlement with the same entities.
This provision requires an additional payment of $25 million to the state of Delaware and the original $50 million settlement if a similar agreement is reached within eight years with another state, amounting to over $50 million. This provision underlines the accountability held by chemical manufacturers in addressing the concerns associated with PFAS contamination.
Legal Battles Surrounding PFAS
Chemical manufacturers have faced numerous lawsuits in recent years regarding alleged PFAS contamination. In a significant ruling, a U.S. appeals court rejected a lower court's decision that would have allowed approximately 11.8 million Ohio residents to sue 10 PFAS manufacturers as a collective group. The legal landscape demonstrates the complexity surrounding PFAS-related claims and the efforts to hold responsible parties accountable for their actions.
In June, 3M agreed to a $10.3 billion settlement to address hundreds of claims alleging the company had contaminated public drinking water with PFAS. Similarly, Chemours, DuPont, and Corteva reached a separate settlement with U.S. water providers, amounting to $1.19 billion.
These settlements underscore the growing recognition within the industry regarding the need to address PFAS-related concerns and the responsibility manufacturers bear in ensuring the safety of their products and practices.
Photo: DuPont Newsroom
